Page last updated: 2024-08-17

galactose and DDD MPGNII

galactose has been researched along with DDD MPGNII in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Fukao, Y; Kano, T; Kato, R; Lee, M; Makita, Y; Nakayama, M; Suzuki, H; Suzuki, Y1
Kopač, M; Meglič, A; Rus, RR1

Other Studies

2 other study(ies) available for galactose and DDD MPGNII

ArticleYear
Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy.
    CEN case reports, 2021, Volume: 10, Issue:1

    Topics: Adult; Antibodies, Monoclonal; Antiviral Agents; Arthritis, Rheumatoid; Crohn Disease; Diagnosis, Differential; Female; Galactose; Glomerulonephritis, IGA; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Hydrocarbons, Fluorinated; Immunoglobulin A; Immunohistochemistry; Kidney; Lupus Erythematosus, Systemic; Male; Middle Aged; Pulse Therapy, Drug; Remission Induction; Steroids; Tonsillectomy; Urea

2021
Partial remission of resistant nephrotic syndrome after oral galactose therapy.
    Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy, 2011, Volume: 15, Issue:3

    Topics: Administration, Oral; Adolescent; Biopsy; Child, Preschool; Drug Resistance; Female; Galactose; Glomerulonephritis, Membranoproliferative; Glomerulosclerosis, Focal Segmental; Glucocorticoids; Humans; Male; Nephrotic Syndrome; Proteinuria; Remission Induction

2011